Pfizer quarterly revenue misses estimates due to sales drop in top drugs
Pfizer, the largest US drug-maker, reported quarterly revenue that missed estimates as sales of its key drugs fell short of expectations. Sales of breast cancer drug Ibrance, which is expected to face competition from rival Novartis’s Kisqali, rose more than 58% to $679m, but missed the consensus estimate of $682m, according to Barclays. "Key franchises came in well below expectations, raising concerns about Pfizer’s ability go grow in the absence of mergers and acquisitions," Goldman Sachs analysts said. Sales of the company’s arthritis drug, Xeljanz, were particularly weak, the analysts said, adding that cancer drug Xtandi and its Prevnar vaccine also came in lower than expectations. Pfizer said three fewer selling days in the quarter, compared with last year, reduced sales by about $300m, surprising some Wall Street analysts. "Pfizer calls out a deficit of selling days ... Given that multiple major products fell just to the short side of our estimates, we are inclined to agree," ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.